Sphingolipid lysosomal storage diseases: from bench to bedside

• Main Authors: Muna Abed Rabbo, Yara Khodour, Laurie S. Kaguni, Johnny Stiban
• Format: Article
• Language: English
• Published: BMC 2021-05-01
• Series: Lipids in Health and Disease
• Subjects: sphingolipids; lysosomal storage diseases; inborn errors of metabolism; neurological diseases; sphingolipidoses; Gaucher
• Online Access: https://doi.org/10.1186/s12944-021-01466-0

Abstract Johann Ludwig Wilhelm Thudicum described sphingolipids (SLs) in the late nineteenth century, but it was only in the past fifty years that SL research surged in importance and applicability. Currently, sphingolipids and their metabolism are hotly debated topics in various biochemical fields. Similar to other macromolecular reactions, SL metabolism has important implications in health and disease in most cells. A plethora of SL-related genetic ailments has been described. Defects in SL catabolism can cause the accumulation of SLs, leading to many types of lysosomal storage diseases (LSDs) collectively called sphingolipidoses. These diseases mainly impact the neuronal and immune systems, but other systems can be affected as well. This review aims to present a comprehensive, up-to-date picture of the rapidly growing field of sphingolipid LSDs, their etiology, pathology, and potential therapeutic strategies. We first describe LSDs biochemically and briefly discuss their catabolism, followed by general aspects of the major diseases such as Gaucher, Krabbe, Fabry, and Farber among others. We conclude with an overview of the available and potential future therapies for many of the diseases. We strive to present the most important and recent findings from basic research and clinical applications, and to provide a valuable source for understanding these disorders.